Tag Archives: interest
#431958 The Next Generation of Cameras Might See ...
You might be really pleased with the camera technology in your latest smartphone, which can recognize your face and take slow-mo video in ultra-high definition. But these technological feats are just the start of a larger revolution that is underway.
The latest camera research is shifting away from increasing the number of mega-pixels towards fusing camera data with computational processing. By that, we don’t mean the Photoshop style of processing where effects and filters are added to a picture, but rather a radical new approach where the incoming data may not actually look like at an image at all. It only becomes an image after a series of computational steps that often involve complex mathematics and modeling how light travels through the scene or the camera.
This additional layer of computational processing magically frees us from the chains of conventional imaging techniques. One day we may not even need cameras in the conventional sense any more. Instead we will use light detectors that only a few years ago we would never have considered any use for imaging. And they will be able to do incredible things, like see through fog, inside the human body and even behind walls.
Single Pixel Cameras
One extreme example is the single pixel camera, which relies on a beautifully simple principle. Typical cameras use lots of pixels (tiny sensor elements) to capture a scene that is likely illuminated by a single light source. But you can also do things the other way around, capturing information from many light sources with a single pixel.
To do this you need a controlled light source, for example a simple data projector that illuminates the scene one spot at a time or with a series of different patterns. For each illumination spot or pattern, you then measure the amount of light reflected and add everything together to create the final image.
Clearly the disadvantage of taking a photo in this is way is that you have to send out lots of illumination spots or patterns in order to produce one image (which would take just one snapshot with a regular camera). But this form of imaging would allow you to create otherwise impossible cameras, for example that work at wavelengths of light beyond the visible spectrum, where good detectors cannot be made into cameras.
These cameras could be used to take photos through fog or thick falling snow. Or they could mimic the eyes of some animals and automatically increase an image’s resolution (the amount of detail it captures) depending on what’s in the scene.
It is even possible to capture images from light particles that have never even interacted with the object we want to photograph. This would take advantage of the idea of “quantum entanglement,” that two particles can be connected in a way that means whatever happens to one happens to the other, even if they are a long distance apart. This has intriguing possibilities for looking at objects whose properties might change when lit up, such as the eye. For example, does a retina look the same when in darkness as in light?
Multi-Sensor Imaging
Single-pixel imaging is just one of the simplest innovations in upcoming camera technology and relies, on the face of it, on the traditional concept of what forms a picture. But we are currently witnessing a surge of interest for systems that use lots of information but traditional techniques only collect a small part of it.
This is where we could use multi-sensor approaches that involve many different detectors pointed at the same scene. The Hubble telescope was a pioneering example of this, producing pictures made from combinations of many different images taken at different wavelengths. But now you can buy commercial versions of this kind of technology, such as the Lytro camera that collects information about light intensity and direction on the same sensor, to produce images that can be refocused after the image has been taken.
The next generation camera will probably look something like the Light L16 camera, which features ground-breaking technology based on more than ten different sensors. Their data are combined using a computer to provide a 50 MB, re-focusable and re-zoomable, professional-quality image. The camera itself looks like a very exciting Picasso interpretation of a crazy cell-phone camera.
Yet these are just the first steps towards a new generation of cameras that will change the way in which we think of and take images. Researchers are also working hard on the problem of seeing through fog, seeing behind walls, and even imaging deep inside the human body and brain.
All of these techniques rely on combining images with models that explain how light travels through through or around different substances.
Another interesting approach that is gaining ground relies on artificial intelligence to “learn” to recognize objects from the data. These techniques are inspired by learning processes in the human brain and are likely to play a major role in future imaging systems.
Single photon and quantum imaging technologies are also maturing to the point that they can take pictures with incredibly low light levels and videos with incredibly fast speeds reaching a trillion frames per second. This is enough to even capture images of light itself traveling across as scene.
Some of these applications might require a little time to fully develop, but we now know that the underlying physics should allow us to solve these and other problems through a clever combination of new technology and computational ingenuity.
This article was originally published on The Conversation. Read the original article.
Image Credit: Sylvia Adams / Shutterstock.com Continue reading
Posted in Human Robots
#431928 How Fast Is AI Progressing? Stanford’s ...
When? This is probably the question that futurists, AI experts, and even people with a keen interest in technology dread the most. It has proved famously difficult to predict when new developments in AI will take place. The scientists at the Dartmouth Summer Research Project on Artificial Intelligence in 1956 thought that perhaps two months would be enough to make “significant advances” in a whole range of complex problems, including computers that can understand language, improve themselves, and even understand abstract concepts.
Sixty years later, and these problems are not yet solved. The AI Index, from Stanford, is an attempt to measure how much progress has been made in artificial intelligence.
The index adopts a unique approach, and tries to aggregate data across many regimes. It contains Volume of Activity metrics, which measure things like venture capital investment, attendance at academic conferences, published papers, and so on. The results are what you might expect: tenfold increases in academic activity since 1996, an explosive growth in startups focused around AI, and corresponding venture capital investment. The issue with this metric is that it measures AI hype as much as AI progress. The two might be correlated, but then again, they may not.
The index also scrapes data from the popular coding website Github, which hosts more source code than anyone in the world. They can track the amount of AI-related software people are creating, as well as the interest levels in popular machine learning packages like Tensorflow and Keras. The index also keeps track of the sentiment of news articles that mention AI: surprisingly, given concerns about the apocalypse and an employment crisis, those considered “positive” outweigh the “negative” by three to one.
But again, this could all just be a measure of AI enthusiasm in general.
No one would dispute the fact that we’re in an age of considerable AI hype, but the progress of AI is littered by booms and busts in hype, growth spurts that alternate with AI winters. So the AI Index attempts to track the progress of algorithms against a series of tasks. How well does computer vision perform at the Large Scale Visual Recognition challenge? (Superhuman at annotating images since 2015, but they still can’t answer questions about images very well, combining natural language processing and image recognition). Speech recognition on phone calls is almost at parity.
In other narrow fields, AIs are still catching up to humans. Translation might be good enough that you can usually get the gist of what’s being said, but still scores poorly on the BLEU metric for translation accuracy. The AI index even keeps track of how well the programs can do on the SAT test, so if you took it, you can compare your score to an AI’s.
Measuring the performance of state-of-the-art AI systems on narrow tasks is useful and fairly easy to do. You can define a metric that’s simple to calculate, or devise a competition with a scoring system, and compare new software with old in a standardized way. Academics can always debate about the best method of assessing translation or natural language understanding. The Loebner prize, a simplified question-and-answer Turing Test, recently adopted Winograd Schema type questions, which rely on contextual understanding. AI has more difficulty with these.
Where the assessment really becomes difficult, though, is in trying to map these narrow-task performances onto general intelligence. This is hard because of a lack of understanding of our own intelligence. Computers are superhuman at chess, and now even a more complex game like Go. The braver predictors who came up with timelines thought AlphaGo’s success was faster than expected, but does this necessarily mean we’re closer to general intelligence than they thought?
Here is where it’s harder to track progress.
We can note the specialized performance of algorithms on tasks previously reserved for humans—for example, the index cites a Nature paper that shows AI can now predict skin cancer with more accuracy than dermatologists. We could even try to track one specific approach to general AI; for example, how many regions of the brain have been successfully simulated by a computer? Alternatively, we could simply keep track of the number of professions and professional tasks that can now be performed to an acceptable standard by AI.
“We are running a race, but we don’t know how to get to the endpoint, or how far we have to go.”
Progress in AI over the next few years is far more likely to resemble a gradual rising tide—as more and more tasks can be turned into algorithms and accomplished by software—rather than the tsunami of a sudden intelligence explosion or general intelligence breakthrough. Perhaps measuring the ability of an AI system to learn and adapt to the work routines of humans in office-based tasks could be possible.
The AI index doesn’t attempt to offer a timeline for general intelligence, as this is still too nebulous and confused a concept.
Michael Woodridge, head of Computer Science at the University of Oxford, notes, “The main reason general AI is not captured in the report is that neither I nor anyone else would know how to measure progress.” He is concerned about another AI winter, and overhyped “charlatans and snake-oil salesmen” exaggerating the progress that has been made.
A key concern that all the experts bring up is the ethics of artificial intelligence.
Of course, you don’t need general intelligence to have an impact on society; algorithms are already transforming our lives and the world around us. After all, why are Amazon, Google, and Facebook worth any money? The experts agree on the need for an index to measure the benefits of AI, the interactions between humans and AIs, and our ability to program values, ethics, and oversight into these systems.
Barbra Grosz of Harvard champions this view, saying, “It is important to take on the challenge of identifying success measures for AI systems by their impact on people’s lives.”
For those concerned about the AI employment apocalypse, tracking the use of AI in the fields considered most vulnerable (say, self-driving cars replacing taxi drivers) would be a good idea. Society’s flexibility for adapting to AI trends should be measured, too; are we providing people with enough educational opportunities to retrain? How about teaching them to work alongside the algorithms, treating them as tools rather than replacements? The experts also note that the data suffers from being US-centric.
We are running a race, but we don’t know how to get to the endpoint, or how far we have to go. We are judging by the scenery, and how far we’ve run already. For this reason, measuring progress is a daunting task that starts with defining progress. But the AI index, as an annual collection of relevant information, is a good start.
Image Credit: Photobank gallery / Shutterstock.com Continue reading
Posted in Human Robots
#431559 Drug Discovery AI to Scour a Universe of ...
On a dark night, away from city lights, the stars of the Milky Way can seem uncountable. Yet from any given location no more than 4,500 are visible to the naked eye. Meanwhile, our galaxy has 100–400 billion stars, and there are even more galaxies in the universe.
The numbers of the night sky are humbling. And they give us a deep perspective…on drugs.
Yes, this includes wow-the-stars-are-freaking-amazing-tonight drugs, but also the kinds of drugs that make us well again when we’re sick. The number of possible organic compounds with “drug-like” properties dwarfs the number of stars in the universe by over 30 orders of magnitude.
Next to this multiverse of possibility, the chemical configurations scientists have made into actual medicines are like the smattering of stars you’d glimpse downtown.
But for good reason.
Exploring all that potential drug-space is as humanly impossible as exploring all of physical space, and even if we could, most of what we’d find wouldn’t fit our purposes. Still, the idea that wonder drugs must surely lurk amid the multitudes is too tantalizing to ignore.
Which is why, Alex Zhavoronkov said at Singularity University’s Exponential Medicine in San Diego last week, we should use artificial intelligence to do more of the legwork and speed discovery. This, he said, could be one of the next big medical applications for AI.
Dogs, Diagnosis, and Drugs
Zhavoronkov is CEO of Insilico Medicine and CSO of the Biogerontology Research Foundation. Insilico is one of a number of AI startups aiming to accelerate drug discovery with AI.
In recent years, Zhavoronkov said, the now-famous machine learning technique, deep learning, has made progress on a number of fronts. Algorithms that can teach themselves to play games—like DeepMind’s AlphaGo Zero or Carnegie Mellon’s poker playing AI—are perhaps the most headline-grabbing of the bunch. But pattern recognition was the thing that kicked deep learning into overdrive early on, when machine learning algorithms went from struggling to tell dogs and cats apart to outperforming their peers and then their makers in quick succession.
[Watch this video for an AI update from Neil Jacobstein, chair of Artificial Intelligence and Robotics at Singularity University.]
In medicine, deep learning algorithms trained on databases of medical images can spot life-threatening disease with equal or greater accuracy than human professionals. There’s even speculation that AI, if we learn to trust it, could be invaluable in diagnosing disease. And, as Zhavoronkov noted, with more applications and a longer track record that trust is coming.
“Tesla is already putting cars on the street,” Zhavoronkov said. “Three-year, four-year-old technology is already carrying passengers from point A to point B, at 100 miles an hour, and one mistake and you’re dead. But people are trusting their lives to this technology.”
“So, why don’t we do it in pharma?”
Trial and Error and Try Again
AI wouldn’t drive the car in pharmaceutical research. It’d be an assistant that, when paired with a chemist or two, could fast-track discovery by screening more possibilities for better candidates.
There’s plenty of room to make things more efficient, according to Zhavoronkov.
Drug discovery is arduous and expensive. Chemists sift tens of thousands of candidate compounds for the most promising to synthesize. Of these, a handful will go on to further research, fewer will make it to human clinical trials, and a fraction of those will be approved.
The whole process can take many years and cost hundreds of millions of dollars.
This is a big data problem if ever there was one, and deep learning thrives on big data. Early applications have shown their worth unearthing subtle patterns in huge training databases. Although drug-makers already use software to sift compounds, such software requires explicit rules written by chemists. AI’s allure is its ability to learn and improve on its own.
“There are two strategies for AI-driven innovation in pharma to ensure you get better molecules and much faster approvals,” Zhavoronkov said. “One is looking for the needle in the haystack, and another one is creating a new needle.”
To find the needle in the haystack, algorithms are trained on large databases of molecules. Then they go looking for molecules with attractive properties. But creating a new needle? That’s a possibility enabled by the generative adversarial networks Zhavoronkov specializes in.
Such algorithms pit two neural networks against each other. One generates meaningful output while the other judges whether this output is true or false, Zhavoronkov said. Together, the networks generate new objects like text, images, or in this case, molecular structures.
“We started employing this particular technology to make deep neural networks imagine new molecules, to make it perfect right from the start. So, to come up with really perfect needles,” Zhavoronkov said. “[You] can essentially go to this [generative adversarial network] and ask it to create molecules that inhibit protein X at concentration Y, with the highest viability, specific characteristics, and minimal side effects.”
Zhavoronkov believes AI can find or fabricate more needles from the array of molecular possibilities, freeing human chemists to focus on synthesizing only the most promising. If it works, he hopes we can increase hits, minimize misses, and generally speed the process up.
Proof’s in the Pudding
Insilico isn’t alone on its drug-discovery quest, nor is it a brand new area of interest.
Last year, a Harvard group published a paper on an AI that similarly suggests drug candidates. The software trained on 250,000 drug-like molecules and used its experience to generate new molecules that blended existing drugs and made suggestions based on desired properties.
An MIT Technology Review article on the subject highlighted a few of the challenges such systems may still face. The results returned aren’t always meaningful or easy to synthesize in the lab, and the quality of these results, as always, is only as good as the data dined upon.
Stanford chemistry professor and Andreesen Horowitz partner, Vijay Pande, said that images, speech, and text—three of the areas deep learning’s made quick strides in—have better, cleaner data. Chemical data, on the other hand, is still being optimized for deep learning. Also, while there are public databases, much data still lives behind closed doors at private companies.
To overcome the challenges and prove their worth, Zhavoronkov said, his company is very focused on validating the tech. But this year, skepticism in the pharmaceutical industry seems to be easing into interest and investment.
AI drug discovery startup Exscientia inked a deal with Sanofi for $280 million and GlaxoSmithKline for $42 million. Insilico is also partnering with GlaxoSmithKline, and Numerate is working with Takeda Pharmaceutical. Even Google may jump in. According to an article in Nature outlining the field, the firm’s deep learning project, Google Brain, is growing its biosciences team, and industry watchers wouldn’t be surprised to see them target drug discovery.
With AI and the hardware running it advancing rapidly, the greatest potential may yet be ahead. Perhaps, one day, all 1060 molecules in drug-space will be at our disposal. “You should take all the data you have, build n new models, and search as much of that 1060 as possible” before every decision you make, Brandon Allgood, CTO at Numerate, told Nature.
Today’s projects need to live up to their promises, of course, but Zhavoronkov believes AI will have a big impact in the coming years, and now’s the time to integrate it. “If you are working for a pharma company, and you’re still thinking, ‘Okay, where is the proof?’ Once there is a proof, and once you can see it to believe it—it’s going to be too late,” he said.
Image Credit: Klavdiya Krinichnaya / Shutterstock.com Continue reading
Posted in Human Robots